Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer

The research and development of non-viral gene therapy has been extensive over the past decade and has received a big push thanks to the recent successful approval of non-viral nucleic acid therapy products. Despite these developments, nucleic acid therapy applications in cancer have been limited. O...

Full description

Saved in:
Bibliographic Details
Published inBiotech (Basel) Vol. 11; no. 1; p. 6
Main Authors Kanvinde, Shrey, Kulkarni, Tanmay, Deodhar, Suyash, Bhattacharya, Deep, Dasgupta, Aneesha
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 07.03.2022
MDPI
Subjects
Acids
Cancer
Cancer therapies
Gene therapy
mRNA
Mutation
nanoparticles
non-viral vectors
nucleic acid delivery
Nucleic acids
polymers
Review
siRNA
Vectors (Biology)
Online AccessGet full text
ISSN2673-6284
2673-6284
DOI10.3390/biotech11010006

Cover

More Information
Summary:The research and development of non-viral gene therapy has been extensive over the past decade and has received a big push thanks to the recent successful approval of non-viral nucleic acid therapy products. Despite these developments, nucleic acid therapy applications in cancer have been limited. One of the main causes of this has been the imbalance in development of delivery vectors as compared with sophisticated nucleic acid payloads, such as siRNA, mRNA, etc. This paper reviews non-viral vectors that can be used to deliver nucleic acids for cancer treatment. It discusses various types of vectors and highlights their current applications. Additionally, it discusses a perspective on the current regulatory landscape to facilitate the commercial translation of gene therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2673-6284
2673-6284
DOI:10.3390/biotech11010006